September 2nd 2025
Supported by Phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.
August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
August 29th 2025
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
August 22nd 2025
New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.
August 22nd 2025
STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.
Targeting a Key Marker of Clotting and Inflammation in COVID-19 Patients
February 15th 2021CalciMedica has developed Auxora, a calcium release-activated calcium (CRAC) channel inhibitor, and it has shown it can reduce the levels of D-dimer, a key biomarker associated with COVID-19 mortality.
Read More
Health Care Workers Hospitalized with COVID-19 May Have Lower Risks
February 8th 2021Health care workers hospitalized with COVID-19 showed no greater risk than the general public for mechanical ventilation or death, and may actually have less risk of ICU admission and shorter hospital stays, a new study found.
Read More
2 Commerce Drive
Cranbury, NJ 08512